HER-2 Expression in Pancreatic Duct Adenocarcinoma

Evaluation of Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 (HER 2) and Its Association With Clinicopathological Variables in Patients With Pancreatic Duct Adenocarcinoma in Upper Egypt

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06055647

Enrollment

Registered

2023-09-28

Start date

2017-01-01

Completion date

2020-12-31

Last updated

2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Adenocarcinoma

Keywords

HER-2, Pancreatic Duct Adenocarcinoma, Immunohistochemistry

Brief summary

Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their subsequent targeting by anti cancer therapeutic modalities may improve patient's survival.

Detailed description

Pancreatic duct adenocarcinoma (PDAC) is a deadly neoplasm that showed current increase in its occurrence. There are many challenges in PDAC; the tumor is frequently associated with perineural invasion and angioinvasion, these lead to early metastasis.Another important challenge is that the tumor is associated with extensive fibrosis that prevents arrival of chemotherapeutic agents. Most modern anti-cancer therapeutic modalities depend on the biologic signature of the tumor. Human epidermal growth factor receptor-2 (HER-2) is a cell surface protein that is associated with enhanced cellular proliferation. HER-2 has been detected and successfully targeted in many human carcinomas as breast and gastric cancers. we aimed to evaluate the potential cancer-promoting effect of HER-2 in PDAC, in order to detect any possible benefits of its targeting by future therapeutic modalities.

Interventions

GENETICimmunohistochemical approach

Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Cases of PDAC who underwent radical operations. 2. Tissue blocks with sufficient material. 3. Cases with available clinical data.

Exclusion criteria

1. Cases of pancreatic carcinoma other than PDAC. 2. Patients who received preoperative chemotherapy or radiotherapy. 3. Patients with PDAC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations. 4. Cases with insufficient/destructed material. 5. Patients with inadequate clinical data.

Design outcomes

Primary

Measure	Time frame	Description
correlation of HRE-2 expression with clinical and pathological parameters	6 months	levels of HER-2 expression will be correlated with clinical parameters (as patients' ages, sexes, tumor location), and pathological parameters (as tumor grades, stages, neural and vascular invasion).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026